ECDC 2016 activities 2016 and 2017 priorities: ENVI Committee, European Parliament Jan 2017

Annual exchange of views at the European Parliment's ENVI Committee with Andrea Ammon, Acting Director

Andrea Ammon, ECDC Acting Director
Annual exchange of views before the ENVI Committee,
31 January 2017, European Parliament, Brussels
ECDC’s activities in 2016 & priorities
for 2017

ECDC Zika virus response
ECDC publications on Zika in 2016 include:
• 9 Rapid Risk Assessments
• 39 Epidemiological updates
• Interim Guidance for healthcare providers & Zika Virus laboratory diagnosis
• Scientific Advice, Policy Briefing & infographics
2

Outbreak of yellow fever in Angola; ECDC
in 1st European Medical Corps deployment
• Deployed at short notice from 10 May to 21 May 2016.
• Luanda and field visits to Huambo and Huila
• Meeting with MoH, WHO Incident Manager, UN, CDC USA, CDC China, MSF,
Cooperacion Cubana with the support of the EU delegation in Angola

Supporting countries in addressing
vaccine hesitancy
Toolkit materials for country adaptation
http://ecdc.europa.eu/en/healthtopics/immunisation/comms-aid/pages/protection.aspx

Life-course vaccination
Ensure protection across life!
Source, image: dreamstime.com

Many people living with HIV have not yet
been diagnosed

PREVENT
More primary HIV
prevention esp for
those most at-risk
TEST
Reach out more
to reduce the
undiagnosed
TREAT
Link more
diagnosed to care
and early treatment
HIV/AIDS - Concerted action needed

ECDC guidance on screening for infectious
diseases among newly arrived migrants to
the EU/EEA
 To prevent and control communicable
diseases among migrant: Ensure access
to healthcare for early diagnosis and
treatment

Current health threats monitored and
assessed by ECDC
ECDC Risk Assessments in January
2017:
- Seasonal Influenza, published on 25
January 2017
- Yellow fever – Brazil, published on 26
January 2017
- Influenza A(H7N9) – China, published
on 27 January 2017
- Zika virus outbreak, soon to be
published.
- Salmonella Enteritidis in Scotland,
soon to be published.
- Salmonella Stourbridge, soon to be
published.
http://ecdc.europa.eu/seasonal-influenza
Weekly infographic on Seasonal Influenza

13
Collaboration between three EU agencies
on surveillance and analysis of data in a
One Health Perspective
•
Joint Interagency Antimicrobial Consumption
and Resistance Analysis report (JIACRA)
First JIACRA report published in January 2015
Second JIACRA report to be published in 2017

Working with international partners
14
Cooperation and capacity building in
enlargement & ENP partner countries
Partnership/MoU with other CDCs
Potential new partner

Always a priority: Protecting the health of
EU citizens
15Source: ECDC, Flickr

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Amanda Mocroft, UCL In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

HIV, drugs and risk behaviour in Europe – what have we learnt and what are th...

1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs. 2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges. 3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to

How are countries in Europe and Central Asia performing against the UNAIDS 90...

Monitoring the EU’s response to the HIV epidemic

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation: ECDC Acting Director Dr Andrea Ammon. a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Vaccine hesitancy in the EU: state of play and impact on vaccination programmes

Community-based HIV testing: the Athens Checkpoint initiative

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Sophocles Chanos In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Fast-tracking the end of AIDS in Europe

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Masoud Dara, WHO Regional Office for Europe In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Experience with the implementation of PrEP in France

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Jean-Michel Molina, Assistance Publique Hôpitaux de Paris In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Valerie Delpech, Public Health Engand In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Scaling up HIV treatment - the Malta experience

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Tonio Piscopo, Mater dei Hospital In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Recent epidemiology and outbreaks in Europe

This document summarizes recent measles outbreaks and epidemiology in Europe. It finds that measles remains endemic in 6 EU countries and that vaccination coverage for the first and second dose of the MMR vaccine remains below 95% in over half of reporting countries. Outbreaks in 2017 have already exceeded case numbers for all of 2016 in some countries. The majority of recent cases are in unvaccinated individuals, especially children ages 1-4 who are the target group for routine vaccination. Several outbreaks have also affected healthcare workers. Actions are needed to strengthen routine childhood vaccination and increase vaccination rates to eliminate measles transmission.

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

- The number of TB cases in the EU/EEA decreased by 30% from 2006 to 2015 while the notification rate decreased by 37% over this period. - The highest notification rate in 2015 was observed in the 25-44 year old age group. Males had higher notification rates than females in most age groups. - Treatment success rates for TB cases remained stable around 72-75% from 2005-2014. The treatment success rate for MDR TB cases was lower at 40.4%.

Scaling up HIV testing: the role of self-testing

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Karen Champenois, Maison Blanche Hospital, Paris In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

HIV: epidemiological challenges in Europe

ECDC Survey on IIS in the EU/EEA

the findings of a survey conducted by ECDC across EU/EEA countries that assessed the level of implementation of IIS and their functionalities, as well as the challenges encountered during the design and implementation. The aim of the survey was to share knowledge about IIS in the EU/EEA in order to build consensus on the characteristics of an optimal system and to describe differences in core functionalities and standards across countries.

HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Teymur Noori, ECDC In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Scaling-up harm reduction services to prevention HIV among people who inject ...

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Mika Salminen, European HA-REACT project In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Priorities for fast tracking the end of AIDS in Europe: Community perspective

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Sini Pasanen, Civil Society Forum/AIDS Action Europe In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

PrEP implementation strategies across Europe – an overview

This document provides an overview of PrEP implementation strategies across Europe from ECDC. It discusses the ECDC's opinion on PrEP and a meeting held in April 2016 on the topic. Key findings from an informal Hornet/ECDC survey on PrEP use in Europe are presented. The status of PrEP implementation in different European countries is outlined, with some countries having implemented or planned demonstration projects, while issues limiting implementation like cost and eligibility criteria are discussed. The discourse around PrEP from a public health perspective is shown to have evolved from questions around efficacy to considerations of affordability, STI risk, and implementation models.

Facilitating HIV testing and linkage to care - the UK experience

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Cary James, Terrence Higgins Trust In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Screening Migrants at Europe’s Forefront: Migrant health and infectious disea...

HIV infection in children and adolescents in the EU/EEA 2015

The document discusses HIV infection among children and adolescents in the European Union and European Economic Area (EU/EEA). It provides statistics on new HIV diagnoses from 2006-2015, showing an increase among adolescents ages 15-19. The majority of infections in children under 15 were due to mother-to-child transmission, while most adolescents were infected through heterosexual sex or sex between men. While mother-to-child transmission rates are declining in EU/EEA-born children, transmission remains high in children born outside the EU/EEA to migrant mothers. The document calls for targeted HIV prevention strategies focusing on at-risk groups.

How can HIV among men who have sex with men be prevented in Europe? Evidence-...

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: ECDC's HIV expert Anastasia Pharris a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

New HIV diagnoses among older adults in the EU/EEA: Missed opportunities and ...

Importance and implication of starting HIV treatment early

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Jens Lundgren, CHIP In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

Hepatitis B and C surveillance in the EU/EEA 2015

HIV among migrants, what do we know?

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Julia del Amo, Instituto de Salud Carlos III, Madrid In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Fast-track the end of AIDS global

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Luis Loures, UNAIDS In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

HIV AIDS Surveillance Report 2015

Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay). This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.

What's hot

Importance of HIV testing and linkage to care

Scaling up HIV treatment - the Malta experience

Recent epidemiology and outbreaks in Europe

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

Scaling up HIV testing: the role of self-testing

HIV: epidemiological challenges in Europe

ECDC Survey on IIS in the EU/EEA

HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...

Scaling-up harm reduction services to prevention HIV among people who inject ...

Priorities for fast tracking the end of AIDS in Europe: Community perspective

PrEP implementation strategies across Europe – an overview

Facilitating HIV testing and linkage to care - the UK experience

Screening Migrants at Europe’s Forefront: Migrant health and infectious disea...

HIV infection in children and adolescents in the EU/EEA 2015

How can HIV among men who have sex with men be prevented in Europe? Evidence-...

New HIV diagnoses among older adults in the EU/EEA: Missed opportunities and ...

Importance and implication of starting HIV treatment early

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

Hepatitis B and C surveillance in the EU/EEA 2015

HIV among migrants, what do we know?

What's hot (20)

Importance of HIV testing and linkage to care

Scaling up HIV treatment - the Malta experience

Recent epidemiology and outbreaks in Europe

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

Scaling up HIV testing: the role of self-testing

HIV: epidemiological challenges in Europe

ECDC Survey on IIS in the EU/EEA

HIV Continuum of Care in the EU/EEA: Findings from Dublin Declaration monitor...

Scaling-up harm reduction services to prevention HIV among people who inject ...

Priorities for fast tracking the end of AIDS in Europe: Community perspective

PrEP implementation strategies across Europe – an overview

Facilitating HIV testing and linkage to care - the UK experience

Screening Migrants at Europe’s Forefront: Migrant health and infectious disea...

HIV infection in children and adolescents in the EU/EEA 2015

How can HIV among men who have sex with men be prevented in Europe? Evidence-...

New HIV diagnoses among older adults in the EU/EEA: Missed opportunities and ...

Importance and implication of starting HIV treatment early

World Tuberculosis Day 2017 - Tuberculosis situation in the EU/EEA, 2015

Hepatitis B and C surveillance in the EU/EEA 2015

HIV among migrants, what do we know?

Viewers also liked

Fast-track the end of AIDS global

HIV AIDS Surveillance Report 2015

HIV and AIDS surveillance in the EU/EEA

Are EU/EEA countries ready to monitor progress on hepatitis C programmes?

1) EU/EEA countries have limited data available for monitoring hepatitis C virus (HCV) programmes due to gaps in testing and mortality data availability. 2) Existing monitoring infrastructure provides opportunities to expand HCV data collection across countries to better measure disease burden. 3) Collaboration between countries and organizations like ECDC and WHO is important to address data gaps and support national monitoring of HCV elimination progress.

Guidance on programmatic management of latent TB infection: applicability for...

This document provides guidance on managing latent tuberculosis (TB) infection in migrants to help low-incidence countries in Europe achieve TB elimination goals. It describes the process used to develop the guidance, including expert meetings, systematic reviews of evidence, mathematical modeling, and cost-effectiveness studies. The guidance addresses screening and treatment of latent TB infection in high-risk groups like migrants and discusses applicability for TB control in migrants, an important consideration for European countries working to eliminate TB.

ECDC – TESSy data access policy, Gaetan Guyodo (ECDC)

Camelia Savulescu: PCV13 effectiveness and overall effect of PCV10/13 vaccina...

Germaine Hanquet: Indirect effect of infant PCV10/13 vaccination on IPD in th...

From Dublin to Rome: 10 years of the HIV epidemic and response in Europe

What Works? – more than 30 years of prevention and control of HIV

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: Annette Verster, WHO In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Joacim Rocklöv: What scenarios for the epidemiological pattern of Zika infect...

HIV prevention and control - the EU is up to the challenge

Fast-track the end of AIDS in the EU - practical evidence-based interventions. Presentation by: John F. Ryan, Director, European Commission, DG SANTE In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.

Viewers also liked (12)

Fast-track the end of AIDS global

HIV AIDS Surveillance Report 2015

HIV and AIDS surveillance in the EU/EEA

Are EU/EEA countries ready to monitor progress on hepatitis C programmes?

Guidance on programmatic management of latent TB infection: applicability for...

ECDC – TESSy data access policy, Gaetan Guyodo (ECDC)

Camelia Savulescu: PCV13 effectiveness and overall effect of PCV10/13 vaccina...

Germaine Hanquet: Indirect effect of infant PCV10/13 vaccination on IPD in th...

From Dublin to Rome: 10 years of the HIV epidemic and response in Europe

What Works? – more than 30 years of prevention and control of HIV

Joacim Rocklöv: What scenarios for the epidemiological pattern of Zika infect...

HIV prevention and control - the EU is up to the challenge

Similar to ECDC 2016 activities 2016 and 2017 priorities: ENVI Committee, European Parliament Jan 2017

Threat of dengue in Europe and strategic measures to control its spread

bonniefernley

This document discusses the threat of dengue in Europe and strategic measures to control its spread. It provides statistics on rising global dengue cases and deaths reported to WHO. Several recent outbreaks of dengue and other mosquito-borne diseases in Europe are mentioned, demonstrating the region's susceptibility. The WHO's global strategy for 2012-2020 aims to reduce dengue mortality and morbidity through integrated surveillance, vector control, vaccination and research. The WHO regional office is working with partners to assist countries through surveillance, prevention and control programs. A three-phased approach of controlling vectors, preventing disease, and limiting spread is recommended, involving coordination between public health authorities and community participation.

Preparing and responding to influenza and other cross border threats, Dr Ilar...

This document discusses the major challenges and deliverables of the European Centre for Disease Prevention and Control (ECDC) from 2005 to 2015. It outlines ECDC's mission to monitor communicable diseases and support public health authorities across Europe. Some of the key challenges ECDC has faced include developing surveillance networks, responding to influenza pandemics and outbreaks of diseases like avian influenza, MERS-CoV, Ebola, and rising antimicrobial resistance. The document evaluates ECDC's role in monitoring seasonal influenza, conducting risk assessments of emerging diseases, and collaborating with other agencies on integrated analysis. It questions whether ECDC is adequately preparing for future challenges like a potential EU member state default, health issues relating

European approach - HA-REACT Joint Action as an exmple_eng

THL

The HA-REACT Joint Action aims to improve prevention and treatment of HIV, HCV, and TB among people who inject drugs in the EU. It has several work packages focused on testing and linkage to care, scaling up harm reduction, improving continuity of care in prisons, and integrated care. Activities conducted so far include training healthcare workers, developing educational materials, assessing harm reduction needs in focus countries, and piloting new services like mobile outreach units and harm reduction programs in prisons. The goal is to build capacity and update national programs to better respond to the needs of people who inject drugs.

Infections among people who inject drugs -- problem solved?

This document summarizes a presentation given by Anastasia Pharris of the European Centre for Disease Prevention and Control on infections among people who inject drugs. It finds that over 30,000 new HIV diagnoses in Europe in 2016 were due to injecting drug use, with most cases concentrated in Eastern Europe. While harm reduction efforts have made progress in some countries, people who inject drugs still face high burdens of HIV, hepatitis C, and other infections. The presentation calls for improved testing, treatment, and prevention programs targeting this group.

The meaning of meningococcal carriage - Slideset by Professor Adam Finn

WAidid

Work of the WHO Regional Office for Europe for public health

Presentation - The impact of Ignac Semmelweis on global health priorities

This document summarizes Dr. Ignac Semmelweis's impact on global health priorities. It discusses how Semmelweis, in the 1800s, discovered that handwashing with chlorine reduced childbed fever and maternal mortality rates. Despite facing criticism, his findings helped establish germ theory and antiseptic practices. Today, hand hygiene and infection prevention remain global priorities to reduce healthcare-associated infections, antimicrobial resistance, and improve maternal and child health outcomes. Semmelweis's legacy demonstrates how simple practices can have enormous impacts on public health.

Emerging and re-emerging infectious diseases: a key issue of governance for h...

Global Risk Forum GRFDavos

Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02

hetalmalaviya

This document discusses emerging infectious diseases and antimicrobial resistance as key issues for health governance in Europe. It provides information on progress made in several areas: 1) Establishing a WHO European action plan to address antimicrobial resistance that has been adopted by all 53 member states. 2) Expanding infectious disease surveillance networks to cover all member states. 3) Collecting region-wide data on antimicrobial use and consumption to support action by countries. 4) Adopting strategies in the European action plan for HIV/AIDS from 2012-2015 to reduce vulnerability and optimize prevention and treatment outcomes.

National AIDS control programme ppt

KomalSingh811671

The document summarizes the National AIDS Control Programme (NACP) in India. It discusses the four phases of NACP from 1992 to 2017, which aimed to prevent the spread of HIV/AIDS and provide treatment. Key aspects included increasing awareness, blood safety measures, condom promotion, prevention of parent-to-child transmission, and expanding access to antiretroviral treatment. The current phase (NACP IV) seeks to reduce new HIV infections by 50% by 2020 through continued prevention efforts and by ensuring treatment for all those who need it.

Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC

DRIVE research

This document summarizes ECDC's work on influenza vaccine effectiveness studies in Europe. It outlines ECDC's strategic objectives related to influenza, which include improving surveillance information, promoting vaccination, and strengthening pandemic preparedness. The document discusses ECDC's priorities for 2019, which focus on transforming influenza surveillance, monitoring vaccination programs, and pandemic preparedness. It provides details on ECDC's influenza outputs and activities for 2019, including surveillance reports, vaccine effectiveness studies, and preparedness assessments.

Signalling and risk assessment of emerging zoonoses in The Netherlands

Antibiotic Guardian Leeds Workshop 2016

4 All of Us

Antibiotic resistance is one of the biggest threats facing us today. Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work. What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians. Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.

Trends on Health-Care Associated Infections and Infection Control in Estonia ...

Kazimierz Murzyn

Regional Director's report on the work of the WHO Regional Office for Europe

Центр громадського здоров'я МОЗ України

This document summarizes the work of the WHO Regional Office for Europe from 2010 to 2014. It outlines the office's strategic priorities, including improving health systems, addressing noncommunicable and communicable diseases, and strengthening emergency preparedness. Key achievements are highlighted, such as increased life expectancy in Europe, declines in premature mortality from noncommunicable diseases, and higher rates of treatment for HIV/AIDS and tuberculosis. Challenges remaining include health inequities and curbing the HIV epidemic. The report emphasizes multisectoral collaboration and a life-course approach to tackle challenges and promote healthier, more equitable and sustainable societies in Europe.

2016 tbc reporte global

Omar Zapata

Es el primero en ser producido en la era de los ODM y la Estrategia de Fin de TB. Proporciona una evaluación de la epidemia de TB y el progreso de la tuberculosis los esfuerzos de diagnóstico, tratamiento y prevención, así como una visión general de la financiación específica por tuberculosis y la investigación. También discute la agenda más amplia de la cobertura universal de salud, la protección social y otros ODM que tienen un impacto en salud. estaban disponibles para 202 países y territorios de datos que representan más del 99% de la población y la tuberculosis en el mundo casos.

Глобальний звіт з туберкульозу ВООЗ 2016

The document is the 2016 Global Tuberculosis Report published by the World Health Organization (WHO). It provides data and analysis on global TB epidemiology, diagnosis and treatment, prevention services, universal health coverage and social determinants as they relate to TB, TB financing, and TB research and development. Key findings include that in 2015 there were an estimated 10.4 million new TB cases worldwide, and 1.4 million people died from TB, making it one of the top 10 causes of death. The report aims to inform and guide efforts to end the global TB epidemic.

Who 2016 global tuberculosis report

romeo pomari juarez

This document is the 2016 Global Tuberculosis Report published by the World Health Organization. It provides an overview of the TB epidemic and progress toward global targets for TB prevention, diagnosis, treatment and funding. Key findings include: - An estimated 10.4 million people fell ill with TB in 2015 and 1.8 million died from the disease. - The burden of TB is highest in the South-East Asia and African regions. India had the largest number of new TB cases globally. - Treatment success for new and relapse TB cases notified in 2014 was 83%, short of the global target of 90%. Treatment success for MDR/RR-TB was only 52%. - Funding for TB prevention and care reached $

Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...

Plan de Calidad para el SNS

Empowering the European Citizen: the ECDC Web Communication

Similar to ECDC 2016 activities 2016 and 2017 priorities: ENVI Committee, European Parliament Jan 2017 (20)

Threat of dengue in Europe and strategic measures to control its spread

Preparing and responding to influenza and other cross border threats, Dr Ilar...

European approach - HA-REACT Joint Action as an exmple_eng

Infections among people who inject drugs -- problem solved?

The meaning of meningococcal carriage - Slideset by Professor Adam Finn

Work of the WHO Regional Office for Europe for public health

Presentation - The impact of Ignac Semmelweis on global health priorities

Emerging and re-emerging infectious diseases: a key issue of governance for h...

Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02

National AIDS control programme ppt

Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC

Signalling and risk assessment of emerging zoonoses in The Netherlands

Antibiotic Guardian Leeds Workshop 2016

Trends on Health-Care Associated Infections and Infection Control in Estonia ...

Regional Director's report on the work of the WHO Regional Office for Europe

2016 tbc reporte global

Глобальний звіт з туберкульозу ВООЗ 2016

Who 2016 global tuberculosis report

Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...

Empowering the European Citizen: the ECDC Web Communication

More from European Centre for Disease Prevention and Control

Tuberculosis situation in the EU/EEA, 2019

- There were 49,752 TB cases notified in 29 EU/EEA countries in 2019, with a notification rate of 9.6 per 100,000 population. The number and rate of TB cases have declined steadily between 2010-2019. - Males had higher notification rates than females across all age groups over 14. The highest rate was in those aged 25-44. - 34.5% of cases were in persons of foreign origin, up from 25.3% in 2010. - Treatment success rates after 12 months of treatment declined from 76.2% in 2009 to 63.7% in 2018.

Tuberculosis situation in the EU/EEA, 2018

HIV AIDS surveillance in Europe 2019- 2018 data

Status of PrEP implementation in Europe (Nov 2019)

The document summarizes the status of pre-exposure prophylaxis (PrEP) implementation in Europe based on data from 2018-2019. It finds that while formal PrEP rollout has been slow, especially in Eastern Europe and Central Asia, there is evidence of significant informal PrEP use across countries. As a result, an estimated 500,000 men who have sex with men (MSM) want or need PrEP but are unable to access it, representing a "PrEP gap" in Europe. Barriers to wider PrEP implementation include cost and lack of public funding in some countries.

90-90-90 Goals in Europe: In Action

The public health response to increasing syphilis trends in Europe

Tuberculosis situation in the EU/EEA, 2017

Situation overview on hepatitis E in the EU/EEA Member States

1) Hepatitis E virus (HEV) infection has emerged as an important public health issue in Europe, with over 21,000 cases reported between 2005-2015 across EU/EEA countries. 2) Surveillance systems and case definitions for HEV vary between countries, but most (20/30) now have specific national surveillance for HEV in place. 3) The majority (98%) of HEV cases in Europe are now locally acquired rather than travel-associated, and over half of all cases are diagnosed in hospitals.

Annual Epidemiological Report for 2017: Sexually Transmitted Diseases

$The attributable fraction of deaths due to viral hepatitis: results from a se...$ $The attributable fraction of deaths due to viral hepatitis: results from a se...$

The attributable fraction of deaths due to viral hepatitis: results from a se...

This document summarizes a presentation on estimating mortality due to viral hepatitis using attributable fractions. It discusses: 1) The WHO reference method which uses national mortality statistics and attributable fraction estimates from GBD to estimate hepatitis-related deaths. 2) A sentinel pilot study conducted in Bulgaria and Portugal to develop local estimates of the attributable fractions of cirrhosis and liver cancer caused by hepatitis B and C. The pilot found the attributable fractions varied between sites. 3) Outcomes from the pilot included improved local mortality estimates and lessons learned for expanding the methodology to other countries through clinical and public health partnerships. Limitations around representing overall populations and assigning morbidity to mortality were also noted.

Surveillance of hepatitis B and C in the EU/EEA – 2017 data

Whole Genome Sequencing in EU Multi-country Foodborne Outbreak Investigation

Respondent Driven Sampling

Respondent Driven Sampling (RDS) is a technique for sampling hard-to-reach populations. It works by having initial participants (seeds) recruit a small number of people from their social networks, who are then eligible to recruit others from their networks. This process continues in successive waves. RDS relies on assumptions about network structure and recruitment behaviors. Analysis adjusts for network size and recruitment patterns. The technique was used to sample migrants in Morocco to estimate HIV, syphilis, and tuberculosis prevalence and understand their demographics, risks, and access to services. Results provided insights to guide health programs for this population.

Online Respondent-Driven Detection (RDD)

What have we overlooked in the epidemiology of antimicrobial resistance in Eu...

HIV/AIDS surveillance in Europe 2018 (2017 data)

The document summarizes HIV/AIDS surveillance data in Europe for 2017. Some key findings are: - 25,353 new HIV diagnoses were reported in 30 EU/EEA countries in 2017. - Sex between men accounted for 38% of new diagnoses, while heterosexual transmission accounted for 33%. - Nearly half (49%) of individuals were diagnosed late, with a CD4 count below 350 cells/mm3. - Migrants accounted for 41% of new diagnoses, many originating from sub-Saharan Africa and Latin America.

Strategies to reduce HIV incidence in Europe

Sexually transmitted infections, EU/EEA, 2016

Tuberculosis situation in the EU/EEA, 2018 - 2016 data

1) 58,994 TB cases were notified in 30 EU/EEA countries in 2016, with a notification rate of 11.4 per 100,000 population. The number and rate of TB cases have declined continuously between 2007-2016. 2) The highest notification rates in 2016 were among those aged 25-44, and males had higher rates than females in all groups over 14. Rates have declined annually by 2-4% in all age groups between 2007-2016. 3) 32.7% of cases in 2016 were in persons of foreign origin, an increase from 21% in 2007. The rate of cases in foreign-born persons was stable between 2007-2016.

Latest epidemiology on migrants in the European Union - ECDC

More from European Centre for Disease Prevention and Control (20)

Tuberculosis situation in the EU/EEA, 2019

Tuberculosis situation in the EU/EEA, 2018

HIV AIDS surveillance in Europe 2019- 2018 data

Status of PrEP implementation in Europe (Nov 2019)

90-90-90 Goals in Europe: In Action

The public health response to increasing syphilis trends in Europe

Tuberculosis situation in the EU/EEA, 2017

Situation overview on hepatitis E in the EU/EEA Member States

Annual Epidemiological Report for 2017: Sexually Transmitted Diseases

$The attributable fraction of deaths due to viral hepatitis: results from a se...$ $The attributable fraction of deaths due to viral hepatitis: results from a se...$

The attributable fraction of deaths due to viral hepatitis: results from a se...

Surveillance of hepatitis B and C in the EU/EEA – 2017 data

Whole Genome Sequencing in EU Multi-country Foodborne Outbreak Investigation

Respondent Driven Sampling

Online Respondent-Driven Detection (RDD)

What have we overlooked in the epidemiology of antimicrobial resistance in Eu...

HIV/AIDS surveillance in Europe 2018 (2017 data)

Strategies to reduce HIV incidence in Europe

Sexually transmitted infections, EU/EEA, 2016

Tuberculosis situation in the EU/EEA, 2018 - 2016 data

Latest epidemiology on migrants in the European Union - ECDC

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf

How to choose the best dermatologists in Indore.

Gokuldas Hospital

Recent advances on Cervical cancer .pptx

DrGirishJHoogar

Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf

MuhammadMuneer49

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf

Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...

AyushGadhvi1

LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES

ShraddhaTamshettiwar

low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g. Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight

What are the different types of Dental implants.

Gokuldas Hospital

Are you looking for a long-lasting solution to your missing tooth? Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf

Ageing, the Elderly, Gerontology and Public Health

phuakl

Tele Optometry (kunj'sppt) / Basics of tele optometry.

Kunj Vihari

How to Control Your Asthma Tips by gokuldas hospital.

Gokuldas Hospital

Breast cancer: Post menopausal endocrine therapy

Dr. Sumit KUMAR

Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options. Diagnosis and Staging The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells. Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions. Treatment Options Endocrine Therapy Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include: Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events. Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen. Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops. Combination Therapies Combining endocrine therapy with other treatments enhances efficacy. Examples include: Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer. Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors. Chemotherapy Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.

Pharmacology of 5-hydroxytryptamine and Antagonist

Dr. Nikhilkumar Sakle

5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness. It is mostly found in the brain, intestines, and blood platelets. 5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin. It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu

HongBiThi1

Artificial Intelligence Symposium (THAIS)

Josep Vidal-Alaball

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1